BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) Director Bihua Chen purchased 312,500 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The stock was bought at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the completion of the transaction, the director owned 3,614,034 shares of the company’s stock, valued at $57,824,544. This represents a 9.47% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
BlossomHill Therapeutics Price Performance
BLSM traded down $0.01 during trading on Monday, reaching $15.99. 417,968 shares of the company were exchanged. BlossomHill Therapeutics, Inc. has a 12-month low of $15.25 and a 12-month high of $17.25.
Recommended Stories
- Five stocks we like better than BlossomHill Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
